At the ESMO 2025 Presidential Symposium, CU Cancer Center’s Sapna Patel, MD, shared promising results from Immatics’ anzu-cel PRAME cell therapy, which achieved a 67% response rate and strong durability in patients with metastatic uveal melanoma.